193 related articles for article (PubMed ID: 6652473)
1. In vivo studies on the basal and evoked release of cholecystokinin and vasoactive intestinal polypeptide from cat cerebral cortex and periventricular structures.
Wang JY; Yaksh TL; Go VL
Brain Res; 1983 Nov; 280(1):105-17. PubMed ID: 6652473
[TBL] [Abstract][Full Text] [Related]
2. Studies on the location and release of cholecystokinin and vasoactive intestinal peptide in rat and cat spinal cord.
Yaksh TL; Abay EO; Go VL
Brain Res; 1982 Jun; 242(2):279-90. PubMed ID: 6896838
[TBL] [Abstract][Full Text] [Related]
3. Studies on the in vivo release of vasoactive intestinal polypeptide (VIP) from the cerebral cortex: effects of cortical, brainstem and somatic stimuli.
Wang JY; Yaksh TL; Go VL
Brain Res; 1985 Feb; 326(2):317-34. PubMed ID: 2982463
[TBL] [Abstract][Full Text] [Related]
4. Coexistence of neuropeptides in projection neurons of the thalamus in the cat.
Sugimoto T; Itoh K; Yasui Y; Kaneko T; Mizuno N
Brain Res; 1985 Nov; 347(2):381-4. PubMed ID: 3904921
[TBL] [Abstract][Full Text] [Related]
5. Release of cholecystokinin from rat cerebral cortex in vivo: role of GABA and glutamate receptor systems.
Yaksh TL; Furui T; Kanawati IS; Go VL
Brain Res; 1987 Mar; 406(1-2):207-14. PubMed ID: 3032357
[TBL] [Abstract][Full Text] [Related]
6. Neurotransmitter modulation of VIP release from cat cerebral cortex.
Wang JY; Yaksh TL; Harty GJ; Go VL
Am J Physiol; 1986 Jan; 250(1 Pt 2):R104-11. PubMed ID: 2867688
[TBL] [Abstract][Full Text] [Related]
7. Immunocytochemical localization of GABA-, cholecystokinin-, vasoactive intestinal polypeptide-, and somatostatin-like immunoreactivity in the area dentata and hippocampus of the rat.
Sloviter RS; Nilaver G
J Comp Neurol; 1987 Feb; 256(1):42-60. PubMed ID: 3819038
[TBL] [Abstract][Full Text] [Related]
8. The distribution of cholecystokinin and vasoactive intestinal peptide in rhesus monkey brain as determined by radioimmunoassay.
Beinfeld MC; Lewis ME; Eiden LE; Nilaver G; Pert CB
Neuropeptides; 1983 Jul; 3(5):337-44. PubMed ID: 6621827
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous measurement of cholecystokinin- and vasoactive intestinal polypeptide-like immunoreactivity from cat frontal cortex in vitro: effect of morphine and D-Ala2-D-Leu5-enkephalin.
Micevychi PE; Go VL; Yaksh TL
Brain Res; 1984 Jan; 291(1):55-62. PubMed ID: 6697185
[TBL] [Abstract][Full Text] [Related]
10. Neuropeptides in the gut: quantification and characterization of cholecystokinin octapeptide-, bombesin- and vasoactive intestinal polypeptide-like immunoreactivities in the myenteric plexus of the guinea-pig small institute.
Hutchison JB; Dimaline R; Dockray GJ
Peptides; 1981; 2(1):23-30. PubMed ID: 6264410
[TBL] [Abstract][Full Text] [Related]
11. Survey of distribution of substance P, vasoactive intestinal polypeptide, cholecystokinin, neurotensin, Met-enkephalin, bombesin and PHI in the spinal cord of cat, dog, sloth and monkey.
Yaksh TL; Michener SR; Bailey JE; Harty GJ; Lucas DL; Nelson DK; Roddy DR; Go VL
Peptides; 1988; 9(2):357-72. PubMed ID: 2453858
[TBL] [Abstract][Full Text] [Related]
12. Co-existence of vasoactive intestinal polypeptide (VIP)- and cholecystokinin (CCK)-like immunoreactivities in thalamocortical neuron in the ventrolateral nucleus of the rat.
Ogawa R; Itoh K; Kaneko T; Mizuno N
Brain Res; 1989 Jun; 490(1):152-6. PubMed ID: 2758323
[TBL] [Abstract][Full Text] [Related]
13. The development of motilin, cholecystokinin and vasoactive intestinal peptide immunoreactivity in the forebrain and hindbrain of the rat, as determined by radioimmunoassay.
Beinfeld MC; Korchak DM; Nilaver G; O'Dorisio TM
Brain Res; 1983 Oct; 312(1):146-50. PubMed ID: 6652504
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal polypeptide (VIP) inhibits potassium-induced release of cholecystokinin (CCK) from rat caudato-putamen but not from cerebral cortex.
Allard LR; Beinfeld MC
Neuropeptides; 1986 Oct; 8(3):287-93. PubMed ID: 3785588
[TBL] [Abstract][Full Text] [Related]
15. Regional distribution of vasoactive intestinal peptide in brains from normal and parkinsonian subjects.
Jégou S; Javoy-Agid F; Delbende C; Tranchand-Bunel D; Coy DH; Agid Y; Vaudry H
Peptides; 1988; 9(4):787-93. PubMed ID: 3226955
[TBL] [Abstract][Full Text] [Related]
16. Marked depression of brain cholecystokinin and vasoactive intestinal polypeptide levels in Eck fistula dogs.
Sato S; Tateishi K; Kato A; Suzuki K; Miura Y; Matsuoka Y; Hamaoka T
Regul Pept; 1989 Apr; 25(1):111-21. PubMed ID: 2717782
[TBL] [Abstract][Full Text] [Related]
17. Neuropeptide content and connectivity of the rat claustrum.
Eiden LE; Mezey E; Eskay RL; Beinfeld MC; Palkovits M
Brain Res; 1990 Jul; 523(2):245-50. PubMed ID: 1976024
[TBL] [Abstract][Full Text] [Related]
18. Cortical peptide changes in Huntington's disease may be independent of striatal degeneration.
Mazurek MF; Garside S; Beal MF
Ann Neurol; 1997 Apr; 41(4):540-7. PubMed ID: 9124812
[TBL] [Abstract][Full Text] [Related]
19. Measurement and characterisation of human cholecystokinin-like immunoreactivity (CCK-LI) in tissues by radioimmunoassay.
Bacarese-Hamilton AJ; Adrian TE; Bloom SR
Clin Chim Acta; 1984 Dec; 144(2-3):213-24. PubMed ID: 6529856
[TBL] [Abstract][Full Text] [Related]
20. In vitro, release of cholecystokinin from hypothalamus and frontal cortex of Sprague-Dawley, Zucker lean (Fa/-) and obese (fa/fa) rats.
Micevych PE; Go VL; Yaksh TL; Finkelstein J
Peptides; 1984; 5(1):73-80. PubMed ID: 6200866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
